Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.
Identifieur interne : 001899 ( PubMed/Corpus ); précédent : 001898; suivant : 001900Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.
Auteurs : Tommy R. TongSource :
- Expert opinion on therapeutic patents [ 1744-7674 ] ; 2009.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : Coronavirus, SARS Virus.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Humans, Patents as Topic.
Abstract
Severe acute respiratory syndrome (SARS) coronavirus emerged from an animal reservoir in 2002 and has the potential to reemerge, as shown by the occurrence of non-laboratory-associated new cases in the winter of 2003. In the absence of a vaccine, broad spectrum anticoronaviral medications are needed.
DOI: 10.1517/13543770802600698
PubMed: 19441924
Links to Exploration step
pubmed:19441924Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.</title><author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name><affiliation><nlm:affiliation>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, 1825 Eastchester Road, Bronx, NY 10461, USA. ttong@montefiore.org</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19441924</idno><idno type="pmid">19441924</idno><idno type="doi">10.1517/13543770802600698</idno><idno type="wicri:Area/PubMed/Corpus">001899</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001899</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.</title><author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name><affiliation><nlm:affiliation>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, 1825 Eastchester Road, Bronx, NY 10461, USA. ttong@montefiore.org</nlm:affiliation></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic patents</title><idno type="eISSN">1744-7674</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Coronavirus (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Patents as Topic</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Patents as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus emerged from an animal reservoir in 2002 and has the potential to reemerge, as shown by the occurrence of non-laboratory-associated new cases in the winter of 2003. In the absence of a vaccine, broad spectrum anticoronaviral medications are needed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19441924</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7674</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on therapeutic patents</Title><ISOAbbreviation>Expert Opin Ther Pat</ISOAbbreviation></Journal><ArticleTitle>Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.</ArticleTitle><Pagination><MedlinePgn>415-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/13543770802600698</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome (SARS) coronavirus emerged from an animal reservoir in 2002 and has the potential to reemerge, as shown by the occurrence of non-laboratory-associated new cases in the winter of 2003. In the absence of a vaccine, broad spectrum anticoronaviral medications are needed.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Anticoronavirals targeting viral entry were reviewed in part I. Here we review anticoronaviral therapies directed against the intracellular life cycle, with an emphasis on allowed patents and pending patents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The published literature, in particular, patent publications is searched for relevant documents. The information is organized and critiqued.</AbstractText><AbstractText Label="RESULTS/CONCLUSION" NlmCategory="CONCLUSIONS">Many promising anticoronaviral strategies are identified. Monoclonal antibodies, protease inhibitors, interferon-based drugs and nucleic-acid based antivirals are most advanced, each having its own advantages and disadvantages. A multi-pronged approach, keeping all venues open, is advocated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Tommy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, 1825 Eastchester Road, Bronx, NY 10461, USA. ttong@montefiore.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Pat</MedlineTA><NlmUniqueID>9516419</NlmUniqueID><ISSNLinking>1354-3776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>147</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19441924</ArticleId><ArticleId IdType="doi">10.1517/13543770802600698</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001899 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001899 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19441924
|texte= Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19441924" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |